Table 5.
Characteristics | Univariate | Multivariate | ||
---|---|---|---|---|
p-Value | HR | 95%CI | p-Value | |
Age (>50 vs ≤50) | 0.089 | 0.323 | 0.094–1.108 | 0.072 |
Menopausal status (pre vs post) | 0.811 | |||
Surgery (mastectomy vs BCS) | 0.711 | |||
Pathology (IDC vs others) | 0.832 | |||
Tumors (≤2 cm vs >2 cm) | 0.218 | 2.087 | 0.542–8.039 | 0.285 |
Nodes involved (negative vs positive) | 0.199 | 2.674 | 0.774–9.238 | 0.120 |
Grade (I–II vs III) | 0.990 | |||
ER (positive vs negative) | 0.930 | 0.786 | 0.236–2.617 | 0.695 |
PR (positive vs negative) | 0.674 | 1.887 | 0.285–12.480 | 0.510 |
Ki67 (≤30% vs >30%) | 0.791 | 0.895 | 0.263–3.041 | 0.859 |
Chemotherapy (EC-T vs others) | 0.575 | |||
Radiation (yes vs no) | 0.923 | |||
Endocrine therapy (yes vs no) | 0.839 | |||
ALC (≥1.8 vs <1.8) | 0.054 | 4.433 | 0.955–20.583 | 0.057 |
NLR (≥1.77 vs <1.77) | 0.037 | 0.338 | 0.068–1.694 | 0.187 |
ANC (≥3.2 vs <3.2) | 0.813 |
Abbreviations: IDC, invasive ductal carcinoma; BCS, breast conserving surgery; ER, estrogen receptor; PR, progestrone receptor; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NLR, neutrophil to lymphocyte ratio.